Review our comprehensive list of published human cancer T-cell epitopes.
Harnessing the Immune System in the Fight Against Cancer
Immunity-Informed Decisions about Cancer Treatments
Guided to recognize cancer cells, the human cellular immune response has the power to mount a fast and fierce attack on tumors. A key aspect of immunotherapeutic strategies is the detailed monitoring of cancer-specific T-cell populations in patients to detect existing or induced immunity, understand immune escape, and track patient response to treatments.
Immudex has specific reagents as well as predefined Dextramer® panels to detect, quantify and isolate these cell populations. Alternatively, design Dextramer® reagents to match your cancer immune monitoring.Learn about our solutions
New Therapies from Unraveled Immune Complexity
Reactions of the immune system to the presence of cancer cells are complex and varied. A diversity of immune cells interact in a collective response, each with different receptor affinities to specific tumor antigens. Elucidating that complexity can reveal new modes of action for potential therapies.
Dextramer® reagents detect and characterize the complete spectrum of cells involved in the cellular immune response, including low-affinity CD8+ and CD4+ T cells.Discover the Dextramer® difference
Existing Cellular Immunotherapies Leverage Different Immune Cells in Personalized Cancer Treatments
T cells that have infiltrated a tumor (TILs) can be isolated, activated, expanded, and reinfused into the patient to mount a strong attack on the tumor. The same cells may also be equipped with a new receptor (TCR) to target specific cancer antigens.
T cells engineered with cancer-targeting chimeric antigen receptors (CARs), with the ability to target a specific protein. They are designed to recognize highly specific antigens and either kill tumor cells or modulate immune responses.
Activated natural killer T (NKT) cells fight cancer directly in an antigen-specific cytotoxic attack. They can also activate other immune cells. The activity of these unique cells is CD1d-dependent, opening the opportunity to detect them in samples.
B cells produce antibodies and act as potent antigen-presenting cells to induce antitumor-specific T-cell responses. With well-defined epitopes and sensitive reagents, diverse B-cell populations can be stratified and their role in immunity revealed.
Mouse Cancer Epitopes
Discover the comprehensive list of murine models and cancer T-cell epitopes.
Discover the impact of Dextramer® technology in case studies in the field of cancer research
Learn about the uses, experiences, and finding in cancer research in our list of publications.